Taken together, these results indicate that bosutinib effectively inhibits NB tumor growth in vivo by blocking the activities of Src and c-Abl and by blocking the PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways. Here, STAT3 is linked to neoplasm.